Auris Medical Holding AG (NASDAQ:EARS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.
According to Zacks, “Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects in advanced clinical development: AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. Auris Medical Holding AG is headquartered in Zug, Switzerland. “
Separately, Roth Capital reissued a “buy” rating and set a $5.00 price objective on shares of Auris Medical Holding AG in a report on Saturday, July 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. Auris Medical Holding AG has a consensus rating of “Hold” and a consensus target price of $3.25.
Auris Medical Holding AG (NASDAQ:EARS) last released its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.09.
ILLEGAL ACTIVITY NOTICE: “Auris Medical Holding AG (EARS) Rating Lowered to Hold at Zacks Investment Research” was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/2956369/auris-medical-holding-ag-ears-rating-lowered-to-hold-at-zacks-investment-research.html.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Virtu KCG Holdings LLC purchased a new stake in shares of Auris Medical Holding AG during the second quarter valued at $101,000. Sabby Management LLC purchased a new stake in shares of Auris Medical Holding AG during the first quarter valued at $133,000. Perceptive Advisors LLC purchased a new stake in shares of Auris Medical Holding AG during the first quarter valued at $368,000. Finally, UBS Oconnor LLC purchased a new stake in shares of Auris Medical Holding AG during the first quarter valued at $909,000. 28.38% of the stock is currently owned by hedge funds and other institutional investors.
About Auris Medical Holding AG
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.
Receive News & Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with MarketBeat.com's FREE daily email newsletter.